CBLL - NASDAQ
CeriBell, Inc.
$17.18
-1.8%CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
At a Glance
Live Snapshotcbll
Gross Profit
Last Annual Value
78.27M
3-Year CAGR
54%
5-Year CAGR
29%
10-Year CAGR
14%
CeriBell, Inc. Competitors Analysis of Gross Profit
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 CeriBell, Inc. NASDAQ:CBLL | 78.27M | 27.1% | N/A | N/A | |
 Treace Medical Concepts, Inc. NASDAQ:TMCI | 169.75M | 3.8% | 17.0% | N/A | |
 Standard BioTools Inc. NASDAQ:LAB | 42.54M | -5.5% | -9.3% | -3.1% | |
 Butterfly Network, Inc. NYSE:BFLY | 45.73M | 39.5% | 21.8% | N/A | |
 Enhabit, Inc. NYSE:EHAB | 497.30M | -0.9% | -3.4% | N/A | |
 OrthoPediatrics Corp. NASDAQ:KIDS | 172.66M | 15.8% | 18.7% | 20.7% | |
 Quantum-Si incorporated NASDAQ:QSI | -3.30M | N/A | N/A | N/A | |
 Semler Scientific, Inc. NASDAQ:SMLR | 51.53M | -5.6% | 1.9% | 24.9% | |
 Varex Imaging Corporation NASDAQ:VREX | 290.50M | 0.0% | 1.4% | N/A | |
 Surmodics, Inc. NASDAQ:SRDX | 93.05M | 15.1% | 17.7% | 8.3% |
CeriBell, Inc. Fair Value Envelope
Related Guides
Continue your CBLL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.